
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of December 2021

Commission File Number: 001-41157

BIONOMICS LIMITED

(Exact Name of Registrant as Specified in Its Charter)

200 Greenhill Road
Eastwood SA 5063
Australia
Tel: +618 8150 7400
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On December 31, 2021, Bionomics Limited (the “Company”) lodged a press release with the Australian Securities Exchange (the “ASX”), as required by the laws and regulations of Australia, announcing the resignation of Mitchell Kaye as a non-executive director of the Company, effective December 31, 2021. The press release is furnished herewith as Exhibit 99.1 to this report on Form 6-K.

On December 31, 2021, in connection with Mitchell Kaye’s resignation described above, the Company lodged a Final Director’s Interest Notice on Appendix 3Z with the ASX, as required by the laws and regulations of Australia, disclosing the interest of Mr. Kaye in securities and contracts of the Company. The Final Director’s Interest Notice is furnished herewith as Exhibit 99.2 to this report on Form 6-K.

Exhibits

99.1 [Press Release dated December 31, 2021](#)

99.2 [Final Director’s Interest Notice](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Bionomics Limited

Date: January 3, 2022

By: /s/ Errol De Souza

Name: Errol De Souza, Ph.D.

Title: Executive Chairman



ABN 53 075 582 740

ASX ANNOUNCEMENT
31 December 2021

Resignation of Director

Bionomics Limited (**Bionomics** or **Company**), a clinical-stage biopharmaceutical company, announced today the resignation of Mr Mitchell Kaye as a Non-Executive Director of the Board of Bionomics Limited effective 31 December 2021.

Mr Kaye resigns under the terms of the agreement through which he was appointed in November 2018, as nominee of BVF Partners L.P (**BVF Nominee**) under the Placement Agreement (**Agreement**) dated 9 November 2018.

The Board would like to thank Mr Kaye for his dedication and service and wishes him well for the future.

Released on authority of the Executive Chairman.

FOR FURTHER INFORMATION PLEASE CONTACT:

General:

Ms Suzanne Irwin
Company Secretary
+61 8 8150 7400
CoSec@bionomics.com.au

About Bionomics Limited

Bionomics (ASX:BNO; Nasdaq:BNOX; OTCQB:BNOEF) is a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the $\alpha 7$ nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder and chronic treatment of Post-Traumatic Stress Disorder. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions.

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity Bionomics Limited
ABN 53 075 582 740

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Mr Mitchell D Kaye
Date of last notice	23 November 2018
Date that director ceased to be director	31 December 2021

Part 1 – Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
Nil

+ See chapter 19 for defined terms.

Appendix 3Z
Final Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of securities
Note: Provide details of the circumstances giving rise to the relevant interest	
Nil	

Part 3 – Director's interests in contracts

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

+ See chapter 19 for defined terms.